Janux Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Janux Therapeutics Inc (JANX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Janux Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 13M vs 296,205M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+214.7% annualized vs trailing 12 months), vs accelerating (+3.6%) for its tracked peer group.
- Profitability: Its -214.0% net margin compares with 16.1% for the peer group.
- Scale: Janux Therapeutics Inc ranks #139 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Janux Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.12M compares with $0.95M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
JANX Sales vs. its Competitors, Q2 2026
With a net margin of -214.01 %, Janux Therapeutics Inc reported lower profitability than its competitors (16.06 %).
Janux Therapeutics Inc generated 0.01 % of the combined sales of its peer group.
API endpoints for this dataset
Janux Therapeutics Inc vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Janux Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Janux Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Janux Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (16) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Janux Therapeutics Inc's competitor groups requires a Commercial License.
Janux Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Janux Therapeutics Inc | - | - | - | Yes |
| Competitors combined (100) | ||||
| High-Confidence Competitors (22) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
JANX Stock Performance relative to its Competitors
JANX Stock Performance relative to High-Confidence Competitors
JANX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | Gossamer Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Janux Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Janux Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Janux Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Janux Therapeutics Inc |
1,109.58 | 13.05 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Astrazeneca Plc |
291,203.66 | 58,739.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
| SUBTOTAL | 3,311,120.41 | 414,576.51 |
Sign in to see all competitors of Janux Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Janux Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Janux Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Janux Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cytomx Therapeutics Inc | Company report | 85% |
| Lilly | Company report | 85% |
| Pfizer | Company report | 85% |
| Sanofi | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Novartis | Company report | 85% |
| AbbVie | Company report | 85% |
| Gilead | Company report | 85% |
| Merck & Co. | Company report | 85% |
| Regeneron | Company report | 85% |
| ADAPTIN BIO, INC. | Company report | 85% |
| Biogen | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Roche/Genentech | Company report | 85% |
| Amgen | Company report | 85% |
| GSK | Company report | 85% |
| Takeda | Company report | 85% |
| Bristol Myers Squibb | Company report | 85% |
| Vir Biotechnology | Company report | 85% |
| Xilio Therapeutics | Company report | 85% |
| Harpoon Therapeutics | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Seattle Genetics | Company report | 85% |
| Pandion Therapeutics | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Revitope Oncology | Company report | 85% |
Company report basis, confidence, active dates and source counts for Janux Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Janux Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Janux Therapeutics Inc .
Janux Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Janux Therapeutics Inc | 1,110 | 119,716 | -941,211 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,204 | 706,847 | 123,141 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| PEERS TOTAL | 3,310,011 | 950,873 | 167,004 |
Sign in to see all peers for Janux Therapeutics Inc .
Janux Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Beone Medicines Ltd | United States 54.39 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Janux Therapeutics Inc .
Janux Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Janux Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Janux Therapeutics Inc ranks #139 of 495 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 139 | Janux Therapeutics Inc | 1,110 | 0.02 % |
Market cap and industry share for the rest of Janux Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Janux Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 134 | Mannkind Corporation | 1,206 | -35.15 % |
| 135 | Rapport Therapeutics Inc | 1,160 | -10.09 % |
| 136 | Gh Research Plc | 1,136 | 35.61 % |
| 137 | Nanobiotix S a | 1,126 | 52.38 % |
| 138 | Maravai Lifesciences Holdings Inc | 1,234 | 12.3% |
| 139 | Janux Therapeutics Inc | 1,110 | -38.85 % |
| 140 | Alto Neuroscience Inc | 1,234 | 12.3% |
| 141 | Compass Pathways Plc | 1,234 | 12.3% |
| 142 | Harrow Inc | 1,234 | 12.3% |
| 143 | Adlai Nortye Ltd | 1,234 | 12.3% |
| 144 | Corvus Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Janux Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Janux Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 1.0x | 4.3x | -3.3x |
| Return on Equity | -10.79 % | industry aggregate | -27.14 % |
| Return on Invested Capital | -7.46 % | -9.82 % (avg) | 2.36 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Janux Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | -6.14 % | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -10.79 % | -6.51 % | -7.93 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Janux Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Janux Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Janux Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Janux Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Janux Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Janux Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Janux Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+214.7% annualized vs trailing 12 months).
Weaknesses
- Return on equity 27.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (51.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Janux Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Janux Therapeutics Inc | 1.05 | 23.03 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
Sign in to see all peers for Janux Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Janux Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Janux Therapeutics Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| PEERS TOTAL | +12.0 % | +24.7 % |
Sign in to see all peers for Janux Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Janux Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Janux Therapeutics Inc | Q2 2026 | - | -57.3 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
Sign in to see all peers for Janux Therapeutics Inc .
Janux Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Janux Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
Sign in to see all peers for Janux Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Janux Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Janux Therapeutics Inc | - | 85.03 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Novartis Ag | 22.73 | 5.61 |
| Astrazeneca Plc | 28.51 | 4.96 |
| Amgen Inc | 28.60 | 6.57 |
| PEERS AVERAGE | 45.54 | 7.99 |
Sign in to see all peers for Janux Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.